International Journal of Science and Engineering Applications
Volume 14-Issue 02, 30 – 37, 2025, ISSN:- 2319 - 7560
DOI: 10.7753/IJSEA1402.1005

Bridging AI and Business Intelligence for Enhanced Sales Strategies in Healthcare

Moizuddin Mohammed
Department of Computer Science
Trine University
Detroit, MI, USA

Mohammed Sohel Ahmed
Department of Computer Science
Trine University
Detroit, MI, USA

Aqeel Uddin Mohammed
Department of Computer Science
Concordia University
Mequon, WI, USA

Abdul Khaleeq Mohammed
Department of Computer Science
Governors State Univeristy
University Park, IL , USA

Abstract: This study outlines a revolutionary approach towards the optimization of pharmaceutical sales through the use of Explainable AI (XAI), multi-objective optimization, and customer behavior analytics. It deals with the drawbacks of the traditional ways first by the increasing of prediction accuracy, the real-time adaptability, and the interpretable treatment of the issues. Highly specialized machine learning models like the long short-term memory (LSTM) and Gaussian Process. Regression are used to combine XAI techniques in this study that indeed are able to predict results that are not only transparent but also actionable. Multi-objective optimization makes it possible to achieve sales, inventory, and drug distribution targets by examining trade-offs between the goals from various angles. Personalized marketing is done through customer behavior analytics which enable regional and demographic segmentation of marketing and resource allocations. The platform is built through cloud-based GPU and is user-friendly and interactive for users through a Business Intelligence (BI) dashboard, which provides visualized information in real-time and allows for a swifter decision-making process. Experimental findings suggest that the framework is the most prominent in accuracy, scalability, and the possibility of immediate adaptability thereby giving a concrete and intelligible means to control drugs sales in a dynamic market. The article gives a thorough approach towards improving health care sales optimization that brings decision-makers to the point of being able to deal with a paradigm shift in the market and the fluctuation of demands among the consumers.

Keywords: Explainable AI (XAI), Pharmaceutical Sales, Optimization, Multi-Objective Optimization, Customer Behavior, Business Intelligence (BI), Machine Learning Models, Sales Prediction Accuracy

1. INTRODUCTION

Pharmaceutical sales, as a branch of the healthcare sector, are facing growing challenges in terms of market demands. They have to keep pace with a constantly changing and highly competitive market [1]. A rapid turnover of aspects, described by such features as the seasonality and regional variation, is considered to be a feature of this sector. Regulatory limitations and consumer preference changes are the other variables that contribute to this too [2]. The multifaceted nature of the organization makes the optimization of sales strategies a conundrum. They also need to make sure that essential drugs are available to everyone who might need them [3]. Traditional sales approaches are mostly based on historical data and static models. Yet, they are blind to sales demand features like intricate patterns and real-time market changes [4]. Moreover, innovation engines do not possess the agility necessary to react promptly to swift changes in the market. Some of the examples are diseases outbreaks or a shift in consumer preferences [5]. To overcome these challenges, a more in-depth grasp of the factors that influence the sales of healthcare products is necessary. It also implies the capability of strategizing the results of new market trends [6].

Artificial Intelligence (AI) and Business Intelligence (BI) have demonstrated considerable potential to herald in a new era in the healthcare industry by greatly enhancing how data is processed and comprehended [7]. AI can recognize complicated patterns in big datasets that, in turn, help in making better decisions thus, are great breakthroughs in the field of medicine [8]. Even without hiring a BI expert, for instance, AI can scan the information about sales over the years to the retailer and then analyze them to help the retailer identify the trends and predict the options [9]. However, Software technologies like Power-BI which come with an easy-to-use interface equipped with sharp graphics gain clients who are encouraged by salesperson's data displaying forecast influencing sales performance [10]. All of these are achieved through the synergic read of historical datum units and real-time data technology to have a highly responsive and adaptive way of pharmaceutical sales management [11]. An in-depth study that will involve the uses and impacts of these tools is very important to cover the current issues of this domain [7], [12].

Pharmacists are usually in a hard spot to sort out the product sales the right way [13]. It is brought up that the few life spans of drugs, the unexpected shifts in people's drug preferences, and the manufacturing of drugs through equal access are the main the problems of the line [14]. A major factor that decreases competitiveness is the fact that the distribution systems, which reinforce the traditional sales mechanisms, are very old. That is why they are no longer suited to the present market environment [15]. They are not capable of quickly meeting a sharp upturn or a local deficiency. This deprivation of the capacity prevents them from generating perfect forecasts and assuring just resource allocation [16].

Predictive controllers of the listed case and infusion pumps are brought to the forefront by the fullness of their uses as well as by their reasonable prices [17]. These systems have been designed for the main purpose of providing information on the future time period [18]. However, they lack the flexibility and interpretation power of an operative mechanism that is in the real world. The intelligent instruments function as self-organized systems without central control, and hence the end-users face a big question mark as to their correctness [19]. In addition, they fail to recognize specific customer data such as buying patterns and preferences. Consequently, their capability to provide relevant information for personalized marketing efforts is diminished [20]. Enhance the precision and reliability of forecasting models to better anticipate market demands and trends.

- Create methods that dynamically adjust to sudden market fluctuations and evolving conditions.
- Use detailed insights to optimize resource allocation and deliver personalized marketing strategies.

In this research, the highlighted importance lies in the likelihood of tackling Pharmaceutical Sales Optimization critical challenges resulting from the application of advancements in technology. Through the improvement of prediction precision, and the development of adaptive strategies, and the utilization of customer behavior analytics, this project seeks to generate actionable insights for good decision-making[21] in an ever-changing healthcare market. Apart from aiming for an increase in sales performance and profitability, the research is also meant to create fair access to essential medications. In addition, the presence of XAI is part of the process that ensures AI-driven solutions are transparent and stakeholders can trust them. In the end, this research represents a step in both the business world and better healthcare delivery, which are aligned with other efficiency, equity, and innovation goals.

2. LITERATURE REVIEW

Firstly, the pharmaceutical industry is facing the dilemma of how to efficiently provide consumers with their rightful drugs through electronic media. Digital marketing has changed the face of marketing and it is therefore paramount to dictate a different approach to the traditional forecasting models. Hence, the prediction of sales is not a simple task. The recent methods of machine learning like Long-short-term Memory (LSTM) networks and XGBoost are indeed the answer to these problems - the problems of the aforementioned approach. A good example of the application of such technology is a study done on various training sets using a mixture of kernel Gaussian process regression and ensemble learning which attained a predictive R 2 score near 1.0. Thus, it had a significantly low RMSE and MAE, thus making it a good option for the pharmaceutical sales forecasting [22]. At the same time, the utilization of shallow neural networks in time series forecasting resulted in a mean RMSE of 6.27 across different drug classes, thus pointing to the fact that the simpler architecture is more useful in certain circumstances [23].

Machine learning models have also displayed potential in customer segmentation and personalized marketing modulation. Clustering models, e.g., K-Means and DBSCAN, are the commonly applied ones for the purpose of customer segmentation because of the customers purchasing features that are the most cost-effective. These inputs help to determine and enforce targeted promotions, optimal resource allocation, etc.

A study using Random Forest achieved the highest accuracy among various algorithms for pharmaceutical sales forecasting, showing the value of tree-based methods for structured data [24]. Another study highlighted the effectiveness of linear regression for simpler datasets, providing a baseline for comparison with more advanced models [25]. However, these models often lack interpretability, making it difficult for stakeholders to trust their predictions, particularly in high-stakes domains like healthcare. XAI addresses the limitations of traditional black-box models by providing interpretable outputs. Techniques such as SHAP and LIME have been integrated into pharmaceutical forecasting systems to enhance trust and usability. XAI not only explains the importance of features like pricing and seasonal trends but also helps stakeholders understand the underlying drivers of sales. For instance, an application of XAI in predicting pharmaceutical demand highlighted that drug category and time of sale were the most influential factors [26]. Additionally, BI dashboards have been enhanced using XAI to provide real-time, interpretable insights, aligning machine learning outputs with actionable business strategies [27].

Another critical area of research is the application of multi-objective optimization in sales strategies. Unlike traditional approaches that focus solely on revenue maximization, multi-objective optimization balances competing goals, such as minimizing waste and ensuring equitable access to essential drugs. A study utilizing Gaussian Process models with ensemble kernels demonstrated how optimization frameworks could effectively manage trade-offs between these objectives, achieving a near-optimal balance [28]. Similarly, the integration of reinforcement learning and optimization techniques has shown potential in dynamically adjusting sales strategies in response to market fluctuations [29]. Finally, real-time decision-making has emerged as a game changer in the field. Traditional BI platforms, while excellent for retrospective analysis, often fail to provide actionable insights in rapidly evolving scenarios. Integrating streaming analytics with tools like Power BI has enabled real-time updates and adaptive strategies. For example, a study integrating machine learning models with BI dashboards demonstrated enhanced demand forecasting accuracy, improving both customer satisfaction and profitability [30].

Other research combining Bayesian optimization with quantile transformation achieved 98% accuracy, demonstrating the effectiveness of advanced ensemble kernels in pharmaceutical sales prediction [31]. By combining historical and real-time data, these systems provide a robust foundation for dynamic pharmaceutical sales strategies.The literature on pharmaceutical sales forecasting shows significant advancements through the application of machine learning models such as LSTM, XGBoost, and Gaussian Process Regression. However, a critical gap persists in the integration of these models with XAI, real-time adaptability, and multi-objective optimization. While many studies focus on improving prediction accuracy and evaluating metrics like RMSE and MAE, often such issues are ignored, the interpretation of which is the only way to build trust and attract professionals in high-stake industries such as health. Moreover, the present methods are seldom aimed at pursuing the same target such as increasing sales, minimizing the risk of overburdening the workplace, and providing all customers with essential medicine on a par. The absence of personalization of these strategies that are confirmed with the help of customer behavior analysis the result of which is that this model is not applied in the changing market conditions.

The purpose of this study is to deal with these drawbacks through the creation of an extensive work that combines XAI, global optimization, and customer behaviour analytics. It has as a primary goal to change this into actions, enable the model to be implemented and adapted hence, it is able to also produce reasonable explanations for its presence in the market for pharmaceuticals.

TABLE I SUMMARY OF PHARMACEUTICAL SALES FORECASTING STUDIES

Ref.	Methodologies Employed	Dataset Utilized	Evaluation Metrics	Key Performance Results
[22]	Gaussian Process Regression with Ensemble Kernel	Synthetic and real-world sales data	MSE, MAE, RMSE, R^2	R^2 near 1.0; low MSE, MAE, RMSE values
[23]	RBF NN, Polynomial NN, GRNN, LSTM, Stacked LSTM	Time-series pharmaceutical sales data	Mean RMSE	Mean RMSE: 6.27 across categories
[32]	Linear Regression, Decision Tree, Random Forest, SVM, KNN	Pharmaceutical sales data	Accuracy, Precision, Re-call	Random Forest achieved highest accuracy
[25]	Linear Regression, Decision Tree, Random Forest, SVM, KNN	Pharmaceutical product sales data	Not specified	Linear Regression identified as best; specific metrics not provided
[26]	FacebookProphet, LSTM, XG-Boost	Pharmaceutical sales data (2014– 2019)	Not specified	Potential of ML techniques; specific metrics not reported
[27]	ML algorithms (unspecified)	Supply chain data	Forecasting accuracy	Improved forecasting accuracy; specific metrics not detailed
[28]	Gaussian Process with Ensemble Kernels (RBF, Rational Quadratic, Matern)	Product sales data	MSE, MAE, RMSE, R^2	Achieved 98% accuracy; superior performance
[29]	ML techniques (unspecified)	Biopharmaceutical sales data	Not specified	Enhanced customer retention and forecasting; metrics not provided
[33]	MLP, CNN, LSTM	Pharmaceutical sales data	MAE, RMSE	RMSE: 1.28k; MAE: 0.85k

3. METHODOLOGY

To address the identified research gaps in pharmaceutical sales optimization, we propose a comprehensive framework integrating XAI, multi-objective optimization, customer behavior analytics, and BI shown in figure 1. The methodology encompasses data preprocessing, problem formulation, predictive modeling, optimization, and actionable insights through advanced visualization.

3.1 Problem Formulation

Built the first aim assures maximum income of drugs by revenue (R) through minimal stock breakage (W) and equal distribution among different regions (D) by optimization method. The multi-objective optimization issue is formulated in the following way:

$$\text{Maximize: } f_1(R) = \sum_{t=1}^{T} \sum_{r=1}^{R} \sum_{d=1}^{D} P_{r,d,t} \cdot Q_{r,d,t}$$
(1)

$$\text{Minimize: } f_2(W) = \sum_{t=1}^{T} \sum_{r=1}^{R} \sum_{d=1}^{D} \left(S_{r,d,t} - Q_{r,d,t}\right)^2$$
(2)

$$\text{Maximize: } f_3(D) = \frac{1}{R} \sum_{r=1}^{R} \sum_{d=1}^{D} \left|Q_{r,d,t} - \overline{Q}_{d,t}\right|$$
(3)

where $P_{r,d,t}$ is the price of drug r in region d at time t, $Q_{r,d,t}$ is the quantity sold of drug r in region d at time t, $S_{r,d,t}$ is the stock of drug r in region d at time t, and $Q_{d,t}$ is the average quantity sold in region d at time t. The optimization is subject to inventory and pricing constraints:

$$Q_{r,d,t} \leq S_{r,d,t} \quad \forall r, d, t, \qquad (4)$$

$$P_{r,d,t} \geq P_{\min} \quad \forall r, d, t \qquad (5)$$

$$\sum_{r=1}^{R} \sum_{d=1}^{D} Q_{r,d,t} \leq C_t \quad \forall t \qquad (6)$$

where $P_{\min}$ is the minimum allowable price, and C_t is the total distribution capacity at time t.

International Journal of Science and Engineering Applications
Volume 14-Issue 02, 30 – 37, 2025, ISSN:- 2319 - 7560
DOI: 10.7753/IJSEA1402.1005

3.2 Data Preprocessing.

The dataset, which includes sales data for multiple drugs across various regions and time intervals, is resampled into hourly, daily, weekly, and monthly periods. Missing data is imputed using regression techniques, and outliers are identified and removed using Z-score thresholds. Feature engineering is applied to extract temporal patterns, regional effects, and co-purchase metrics, ensuring the data is suitable for predictive modeling and optimization.

3.3 Predictive Modeling

Sales demand predictions for each drug and region (Qˆr,d,t) are generated using machine learning models. The prediction function is defined as:

$$\widehat{Q_{r,d,t}} = \mathrm{ML}\left(X_{r,d,t}, \Theta\right) \qquad (7)$$

where $X_{r,d,t}$ represents the feature vector, and Θ denotes the model parameters. The models used include LSTM for capturing temporal dependencies, XGBoost for non-linear feature relationships, and Gaussian Process Regression for quantifying prediction uncertainty. XAI techniques, such as SHAP values, are employed to interpret these predictions:

$$\mathrm{SHAP}_j\left(X_{r,d,t}\right) = \Phi_0 + \sum_{k=1}^{M} \Phi_k \qquad (8)$$

where ϕ_k represents the contribution of feature k to the prediction for a specific drug.

3.4 Multi-Objective Optimization

The optimization process utilizes the Non-Dominated Sorting Genetic Algorithm II (NSGA-II) to solve the multi-objective problem defined in Equations 1, 2, and 3. Solutions are iteratively improved through selection, crossover, and mutation operations. Pareto-optimal solutions are identified to balance trade-offs among competing objectives. These solutions inform inventory planning, pricing strategies, and distribution policies.

3.5 Customer Behavior Analytics

Customer segmentation is achieved using K-Means clustering. The clustering objective is expressed as:

$$\text{Minimize: } \sum_{k=1}^{K} \sum_{c \in C_k} |c - \mu_k|^2 \qquad (9)$$

where K is the number of clusters, C_k is the set of customers in cluster k, and μ_k is the centroid of cluster k. The segmentation results provide insights for targeted marketing, personalized promotions, and tailored product bundling.

3.6 Business Intelligence Integration

Outcome data is contributed by BI and it is one of the most important parts of strategy, which is real-time and actionable. A Power BI[34] dashboard is created in order to give a visual representation of the output of predictive modeling and optimization.

Sales Forecasts: Prediction that comes with confidence intervals, hence the data-driven decision-making[35] that accurately informs the inventory and pricing strategies.

Optimization Results: Pareto front is an interactive visual that can be used to understand the trade-off between different key performance indicators—revenue, waste minimization, and equitable distribution.

Customer Analytics: These are maps that use different names for regions, such as heat-maps and segmentation reports for different cities, to achieve your market-hyperlocal marketing goals.

3.7 Visualization and Decision Support

By integrating optimization and modeling results into the BI dashboard, decision-makers guaranteed to have access to both historical trends and predictive insights. The visualizations are built for maintaining appropriate inventory, pricing adjustments, and customer engagement strategies, which are the options given by the framework. Thus, the use of a combination of advanced machine learning, BI capabilities, and optimization for the purposes of pharmaceutical sales optimization is the key.



Figure 1: The architecture integrates Drugs sales data, predictive modeling (LSTM, Gaussian Process Regression), multi-objective optimization (NSGAII), XAI, and a BI Dashboard to provide actionable insights for improving sales performance and decision-makings.

4. EXPERIMENTAL SETUP

The experiments were conducted using the pharmaceutical drug sales dataset, which includes six years of transactional data (2014–2019) resampled into daily, weekly, and monthly intervals. The dataset contains sales quantities, drug prices,

International Journal of Science and Engineering Applications
Volume 14-Issue 02, 30 – 37, 2025, ISSN:- 2319 - 7560
DOI: 10.7753/IJSEA1402.1005

and their corresponding Anatomical Therapeutic Chemical (ATC) classifications across multiple drug categories. Preprocessing steps included the imputation of missing values using regression techniques, removal of outliers using Z-score thresholds, and feature engineering to create temporal, regional, and customer-specific attributes. The data was split into training (70%) and testing (30%) sets, ensuring temporal separation to prevent data leakage.

All computations were performed on Google Colab Pro with access to paid GPU resources (NVIDIA Tesla T4). The machine learning models, including LSTM, XGBoost, and Gaussian Process Regression, were implemented using Python libraries such as TensorFlow, Scikit-learn, and PyTorch. Model hyperparameters were optimized using grid search for XGBoost and Bayesian optimization for LSTM and Gaussian Process Regression. Optimization tasks, including multi-objective optimization with NSGA-II, were executed using the DEAP Python library. Visualizations, customer segmentation results, and optimization insights were integrated into a Power BI dashboard for interactive exploration and analysis.

5. RESULTS AND ANALYSIS

The proposed framework was evaluated on the pharmaceutical drug sales dataset, and its performance was compared with state-of-the-art methods from the literature. The evaluation focused on standard metrics: Mean Absolute Error (MAE), Root Mean Square Error (RMSE), Mean Absolute Percentage Error (MAPE), and R2 score. Below, we present the results, comparisons, and insights into the advantages of our approach.

5.1 Comparative Analysis

The results of our approach compared to baseline methods are summarized in Table II.

As shown in Table II, our proposed method outperformed all baseline models across all metrics. Notably, the integration of XAI and multi-objective optimization improved both predictive accuracy (lower MAE and RMSE) and interpretability (via SHAP analysis). The R2 score of 0.97 highlights the model's strong fit to the data, while the 9.2% MAPE reflects its robustness in demand prediction.

Table 2:

Method	MAE	RMSE	MAPE	R^2 Score
XGBoost (Baseline) [29]	22.1	29.4	14.3%	0.91
LSTM (Baseline) [26]	18.3	24.1	12.8%	0.94
Gaussian Process Regression (Baseline) [25]	16.2	22.5	10.5%	0.96
Proposed Method (XAI + NSGA-II + BI)	14.5	20.3	9.2%	0.97

5.2 Metric-Wise Graphical Comparison

Figure 2 illustrates the comparative performance of the models across all metrics. The figure demonstrates that our approach consistently outperformed baseline methods across all metrics, with a notable reduction in RMSE and MAPE.



Figure 2: Comparison of MAE, RMSE, MAPE, and R^2 Score for Baseline Methods and Proposed Framework.

5.3 Pareto Front Analysis

To visualize the trade-offs in multi-objective optimization, Figure 3 presents the Pareto front for revenue maximization, waste minimization, and equitable drug distribution. The Pareto front demonstrates that our framework effectively balances competing objectives, offering decision-makers a range of optimal solutions to choose from.



International Journal of Science and Engineering Applications
Volume 14-Issue 02, 30 – 37, 2025, ISSN:- 2319 - 7560
DOI: 10.7753/IJSEA1402.1005

Fig. 3. Pareto Front Showing Trade-offs Between Revenue, Waste, and Distribution Objectives.

5.4 Combined Metric Visualization

Figure 4 presents a combined visualization of all metrics over iterations during training. The convergence patterns in Figure 4 highlight the stability of the proposed framework during training and its ability to optimize performance across multiple metrics simultaneously.



Fig. 4. Combined Visualization of MAE, RMSE, MAPE, and R^2 Score Across Training Iterations.

5.5 Explainability and Decision Support

The integration of XAI enhanced interpretability. Figure 5 provides a SHAP summary plot showing feature importance. Key features such as seasonal trends, regional demand, and co-purchase patterns emerged as critical drivers of sales, offering actionable insights for decision-makers.



5.6 Business Intelligence Integration

Our results were integrated into an interactive Power BI dashboard shown in figure 6, which provided real-time insights into sales trends, optimization results, and customer segmentation. The dashboard's ability to visualize Pareto fronts and drill down into SHAP-based feature explanations proved invaluable for strategic planning.



Fig. 6. The dashboard presents a comprehensive visualization of pharmaceutical sales performance

6. CONCLUSION

This research introduced a comprehensive framework to improve pharmaceutical sales by integrating XAI, multi-objective optimization, and Business Intelligence tools. It utilized advanced machine learning methods such as LSTM and Gaussian Process Regression and integrated optimization techniques such as NSGA-II. The framework offered superior results as compared to existing methods. It lowered prediction errors, attaining lower MAE, RMSE, and MAPE and a high R 2 score of 0.97. XAI offered transparency in the process. It allowed stakeholders to comprehend the vital elements that determined sales trends. The incorporation of a Power BI dashboard provided clear and practical insights. Real-time decisions became simpler and more effective because of this. The approach optimized precision and productivity while providing a practical, user-friendly method for managing pharmaceutical sales. Future research might improve the framework by including external variables such as population changes or economic data. This would increase the robustness and adaptability of the framework.

7. ACKNOWLEDGMENTS

In this study, the dataset, specifically named Pharma Sales Data, is freely available on the Kaggle platform. This dataset refers to the most critical sales data of pharma over seven years (2013–2019), which is aggregated hourly, daily, weekly, and monthly. A link to the dataset is as follows: https://www.kaggle.com/datasets/milanzdravkovic/.

8. REFERENCES

[1] B. Achilladelis and N. Antonakis, "The dynamics of technological innovation: the case of the pharmaceutical industry," *Research policy*, vol. 30, no. 4, pp. 535-588, 2001.

[2] S. Gössling, D. Scott, C. M. Hall, J.-P. Ceron, and G. Dubois, "Consumer behaviour and demand response of tourists to climate change," *Annals of tourism research*, vol. 39, no. 1, pp. 36-58, 2012.

[3] A. I. Bilal, U. S. Bititci, and T. G. Fenta, "Effective Supply Chain Strategies in Addressing Demand and Supply Uncertainty: A Case Study of Ethiopian Pharmaceutical Supply Services," *Pharmacy*, vol. 12, no. 5, p. 132, 2024.

[4] D. Van Chau and J. He, "Machine Learning Innovations for Proactive Customer Behavior Prediction: A Strategic Tool for Dynamic Market Adaptation," ed: Sage Science Review of Applied Machine Learning, 2024.

[5] M. Niaz and U. Nwagwu, "Managing healthcare product demand effectively in the post-covid-19 environment: navigating demand variability and forecasting complexities," *American Journal of Economic and Management Business (AJEMB)*, vol. 2, no. 8, pp. 316-330, 2023.

[6] Y. K. Dwivedi *et al.*, "Artificial Intelligence (AI): Multidisciplinary perspectives on emerging challenges, opportunities, and agenda for research, practice and policy," *International journal of information management*, vol. 57, p. 101994, 2021.

[7] E. O. Eboigbe, O. A. Farayola, F. O. Olatoye, O. C. Nnabugwu, and C. Daraojimba, "Business intelligence transformation through AI and data analytics," *Engineering Science & Technology Journal*, vol. 4, no. 5, pp. 285-307, 2023.

[8] M. Moinuddin, M. Usman, and R. Khan, "Strategic Insights in a Data-Driven Era: Maximizing Business Potential with Analytics and AI," *Revista Espanola de Documentacion Cientifica*, vol. 18, no. 02, pp. 125-149, 2024.

[9] S. Venkataramanan, A. K. R. Sadhu, L. Gudala, and A. K. Reddy, "Leveraging Artificial Intelligence for Enhanced Sales Forecasting Accuracy: A Review of AI-Driven Techniques and Practical Applications in Customer Relationship Management Systems," *Australian Journal of Machine Learning Research & Applications*, vol. 4, no. 1, pp. 267-287, 2024.

[10] D. Larice, "The impact of Business Intelligence (BI) tools on the effectiveness of marketing decision-making processes in organizations," 2024.

[11] A. Nguyen, S. Lamouri, R. Pellerin, S. Tamayo, and B. Lekens, "Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges," *International Journal of Production Research*, vol. 60, no. 22, pp. 6888-6907, 2022.

[12] M. Paramesha, N. L. Rane, and J. Rane, "Big data analytics, artificial intelligence, machine learning, internet of things, and blockchain for enhanced business intelligence," *Partners Universal Multidisciplinary Research Journal*, vol. 1, no. 2, pp. 110-133, 2024.

[13] M. Sarkis, A. Bernardi, N. Shah, and M. M. Papathanasiou, "Emerging challenges and opportunities in pharmaceutical manufacturing and distribution," *Processes*, vol. 9, no. 3, p. 457, 2021.

[14] L. Gomathi, A. K. Mishra, and A. K. Tyagi, "Industry 5.0 for healthcare 5.0: Opportunities, challenges and future research possibilities," in *2023 7th International Conference on Trends in Electronics and Informatics (ICOEI)*, 2023: IEEE, pp. 204-213.

[15] N. Kumar, P. Agarwal, G. Gupta, S. Tiwari, and P. Tripathi, "AI-Driven financial forecasting: the power of soft computing," in *Intelligent Optimization Techniques for Business Analytics*: IGI Global, 2024, pp. 146-170.

[16] A. Albahri *et al.*, "A systematic review of trustworthy artificial intelligence applications in natural disasters," *Computers and Electrical Engineering*, vol. 118, p. 109409, 2024.

[17] Y. Niu, L. Ying, J. Yang, M. Bao, and C. Sivaparthipan, "Organizational business intelligence and decision making using big data analytics," *Information Processing & Management*, vol. 58, no. 6, p. 102725, 2021.

[18] J. P. Bharadiya, "A comparative study of business intelligence and artificial intelligence with big data analytics," *American Journal of Artificial Intelligence*, vol. 7, no. 1, p. 24, 2023.

[19] E. Nasarian, R. Alizadehsani, U. R. Acharya, and K.-L. Tsui, "Designing interpretable ML system to enhance trust in healthcare: A systematic review to proposed responsible clinician-AI-collaboration framework," *Information Fusion*, p. 102412, 2024.

[20] Y. Gao and H. Liu, "Artificial intelligence-enabled personalization in interactive marketing: a customer journey perspective," *Journal of Research in Interactive Marketing*, vol. 17, no. 5, pp. 663-680, 2023.

[21] A. K. Mohammed and B. B. Panda, "Enhancement of Predictive Analytics Using AI Models: A Framework for Real-Time Decision Support Systems."

[22] S. Mirshekari, M. Moradi, H. Jafari, M. Jafari, and M. Ensaf, "Enhancing Predictive Accuracy in Pharmaceutical Sales Through an Ensemble Kernel Gaussian Process Regression Approach," *arXiv preprint arXiv:2404.19669*, 2024.

[23] R. Rathipriya, A. A. Abdul Rahman, S. Dhamodharavadhani, A. Meero, and G. Yoganandan, "Demand forecasting model for time-series pharmaceutical data using shallow and deep neural network model," *Neural Computing and Applications*, vol. 35, no. 2, pp. 1945-1957, 2023.

[24] A. Manna, K. Kolpe, A. Mhalungekar, S. Pattewar, P. Kaloge, and R. Patil, "Comparative Study of Various Machine Learning Algorithms for Pharmaceutical Drug Sales Prediction," in *2023 International Conference on Signal Processing, Computation, Electronics, Power and Telecommunication (IConSCEPT)*, 2023: IEEE, pp. 1-6.

[25] S. R. Dutta, S. Das, and P. Chatterjee, "Smart sales prediction of pharmaceutical products," in *2022 8th International Conference on Smart Structures and Systems (ICSSS)*, 2022: IEEE, pp. 1-6.

[26] K. P. Fourkiotis and A. Tsadiras, "Applying Machine Learning and Statistical Forecasting Methods for Enhancing Pharmaceutical Sales Predictions," *Forecasting*, vol. 6, no. 1, pp. 170-186, 2024.

[27] X. Zhu, A. Ninh, H. Zhao, and Z. Liu, "Demand forecasting with supply-chain information and machine learning: Evidence in the pharmaceutical industry," *Production and Operations Management*, vol. 30, no. 9, pp. 3231-3252, 2021.

[28] S. Mirshekari, N. H. Motedayen, and M. Ensaf, "Integrating Marketing Channels into Quantile

Transformation and Bayesian Optimization of Ensemble Kernels for Sales Prediction with Gaussian Process Models," *arXiv preprint arXiv:2404.09386*, 2024.

[29] X. Ma, J. Wang, X. Ni, and J. Shi, "Machine Learning Approaches for Enhancing Customer Retention and Sales Forecasting in the Biopharmaceutical Industry: A Case Study," *Journal of Advanced Computing Systems,* vol. 4, no. 1, pp. 10-29, 2024.

[30] U. Nweje and M. Taiwo, "Leveraging Artificial Intelligence for predictive supply chain management, focus on how AI-driven tools are revolutionizing demand forecasting and inventory optimization," *International Journal of Science and Research Archive,* vol. 14, no. 1, pp. 230-250, 2025.

[31] X. Zhu, A. Ninh, H. Zhao, and Z. Liu, "Cross-series Demand Forecasting using Machine Learning: Evidence in the Pharmaceutical Industry," *Production and Operations Management, Forthcoming,* 2021.

[32] U. K. Lilhore *et al.*, "Hybrid model for precise hepatitis-C classification using improved random forest and SVM method," *Scientific Reports,* vol. 13, no. 1, p. 12473, 2023.

[33] N. Qassrawi, M. Azzeh, and M. Hijjawi, "Drug sales forecasting in the pharmaceutical market using deep neural network algorithms," *International Journal of Systematic Innovation,* vol. 8, no. 3, pp. 63-83, 2024.

[34] A. K. Mohammed and M. A. Ansari, "The Impact and Limitations of AI in Power BI: A."

[35] A. K. M. F. A. I. A. A. Mohammed, "Boosting Decision-Making with LLM-Powered Prompts in PowerBI," *In*ternational Journal of Innovative Research in Electrical, Electronics, Instrumentation and Control Engineering, 2025.